Medical Virology of Hepatitis B: How It Began and Where We Are Now

Overview

Journal Virol J

Publisher Biomed Central

Specialty Microbiology

Date 2013 Jul 23

PMID 23870415

Citations 121

Authors

Wolfram H Gerlich

Affiliations

Soon will be listed here.

Abstract

Infection with hepatitis B virus (HBV) may lead to acute or chronic hepatitis. HBV infections were previously much more frequent but there are still 240 million chronic HBV carriers today and ca. 620,000 die per year from the late sequelae liver cirrhosis or hepatocellular carcinoma. Hepatitis B was recognized as a disease in ancient times, but its etiologic agent was only recently identified. The first clue in unraveling this mystery was the discovery of an enigmatic serum protein named Australia antigen 50 years ago by Baruch Blumberg. Some years later this was recognized to be the HBV surface antigen (HBsAg). Detection of HBsAg allowed for the first time screening of inapparently infected blood donors for a dangerous pathogen. The need to diagnose clinically silent HBV infections was a strong driving force in the development of modern virus diagnostics. HBsAg was the first infection marker to be assayed with a highly sensitive radio immune assay. HBV itself was among the first viruses to be detected by assay of its DNA genome and IgM antibodies against the HBV core antigen were the first to be selectively detected by the anti-μ capture assay. The cloning and sequencing of the HBV genome in 1978 paved the way to understand the viral life cycle, and allowed development of efficient vaccines and drugs. Today's hepatitis B vaccine was the first vaccine produced by gene technology. Among the problems that still remain today are the inability to achieve a complete cure of chronic HBV infections, the recognition of occult HBV infections, their potential reactivation and the incomplete protection against escape mutants and heterologous HBV genotypes by HBV vaccines.

Citing Articles

Immunologically effective biomaterials-enhanced vaccines against infection of pathogenic microorganisms.

Wei Q, Liu S, Huang X, Xin H, Ding J Biosaf Health. 2025; 5(1):45-61.

PMID: 40078604 PMC: 11894984. DOI: 10.1016/j.bsheal.2022.11.002.

From the Cytoplasm into the Nucleus-Hepatitis B Virus Travel and Genome Repair.

Ringlander J, Rydell G, Kann M Microorganisms. 2025; 13(1.

PMID: 39858925 PMC: 11767736. DOI: 10.3390/microorganisms13010157.

Diversity of HBV genotypes and their association with precore/basal core mutations among HBsAg-positive patients in Ibadan, Nigeria.

Faneye A, Motayo B, Mustafa A, Odiabo G Access Microbiol. 2024; 6(11).

PMID: 39525359 PMC: 11542583. DOI: 10.1099/acmi.0.000821.v3.

Conformationally Constrained Isoquinolinones as Orally Efficacious Hepatitis B Capsid Assembly Modulators.

Mesaros E, Cole A, Kultgen S, Mani N, Fan K, Dugan B ACS Med Chem Lett. 2024; 15(9):1627-1634.

PMID: 39291037 PMC: 11403741. DOI: 10.1021/acsmedchemlett.4c00388.

An overview of occult hepatitis B infection (OBI) with emphasis on HBV vaccination.

Delghandi S, Raoufinia R, Shahtahmasbi S, Meshkat Z, Gouklani H, Gholoobi A Heliyon. 2024; 10(17):e37097.

PMID: 39281486 PMC: 11402251. DOI: 10.1016/j.heliyon.2024.e37097.

References

Andernach I, Nolte C, Pape J, Muller C . Slave trade and hepatitis B virus genotypes and subgenotypes in Haiti and Africa. Emerg Infect Dis. 2009; 15(8):1222-8. PMC: 3467954. DOI: 10.3201/eid1508.081642. View

Flehmig B, Ranke M, Berthold H, GERTH H . A solid-phase radioimmunoassay for detection of IgM antibodies to hepatitis A virus. J Infect Dis. 1979; 140(2):169-75. DOI: 10.1093/infdis/140.2.169. View

Maupas P, Goudeau A, Coursaget P, Drucker J, BAGROS P . Immunisation against hepatitis B in man. Lancet. 1976; 1(7974):1367-70. DOI: 10.1016/s0140-6736(76)93023-3. View

Blaich A, Manz M, Dumoulin A, Schuttler C, Hirsch H, Gerlich W . Reactivation of hepatitis B virus with mutated hepatitis B surface antigen in a liver transplant recipient receiving a graft from an antibody to hepatitis B surface antigen- and antibody to hepatitis B core antigen-positive donor. Transfusion. 2012; 52(9):1999-2006. PMC: 3465803. DOI: 10.1111/j.1537-2995.2011.03537.x. View

Tabuchi A, Tanaka J, Katayama K, Mizui M, Matsukura H, Yugi H . Titration of hepatitis B virus infectivity in the sera of pre-acute and late acute phases of HBV infection: transmission experiments to chimeric mice with human liver repopulated hepatocytes. J Med Virol. 2008; 80(12):2064-8. DOI: 10.1002/jmv.21320. View

Summers J, Mason W . Replication of the genome of a hepatitis B--like virus by reverse transcription of an RNA intermediate. Cell. 1982; 29(2):403-15. DOI: 10.1016/0092-8674(82)90157-x. View

SOULIER J . Further data on HBs antigen subtypes - geographical distribution. Vox Sang. 1974; 27(6):533-49. DOI: 10.1111/j.1423-0410.1974.tb02451.x. View

Mason W, Liu C, Aldrich C, Litwin S, Yeh M . Clonal expansion of normal-appearing human hepatocytes during chronic hepatitis B virus infection. J Virol. 2010; 84(16):8308-15. PMC: 2916518. DOI: 10.1128/JVI.00833-10. View

Sells M, Chen M, Acs G . Production of hepatitis B virus particles in Hep G2 cells transfected with cloned hepatitis B virus DNA. Proc Natl Acad Sci U S A. 1987; 84(4):1005-9. PMC: 304350. DOI: 10.1073/pnas.84.4.1005. View

10.

Galbraith R, Eddleston A, Williams R, Zuckerman A . Fulminant hepatic failure in leukaemia and choriocarcinoma related to withdrawal of cytotoxic drug therapy. Lancet. 1975; 2(7934):528-30. DOI: 10.1016/s0140-6736(75)90897-1. View

11.

SZMUNESS W, Stevens C, Harley E, Zang E, Oleszko W, William D . Hepatitis B vaccine: demonstration of efficacy in a controlled clinical trial in a high-risk population in the United States. N Engl J Med. 1980; 303(15):833-41. DOI: 10.1056/NEJM198010093031501. View

12.

Beasley R, Hwang L, Lin C, Chien C . Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22 707 men in Taiwan. Lancet. 1981; 2(8256):1129-33. DOI: 10.1016/s0140-6736(81)90585-7. View

13.

Lanford R, Chavez D, Brasky K, Burns 3rd R, Rico-Hesse R . Isolation of a hepadnavirus from the woolly monkey, a New World primate. Proc Natl Acad Sci U S A. 1998; 95(10):5757-61. PMC: 20452. DOI: 10.1073/pnas.95.10.5757. View

14.

Kock J, Nassal M, MacNelly S, Baumert T, Blum H, von Weizsacker F . Efficient infection of primary tupaia hepatocytes with purified human and woolly monkey hepatitis B virus. J Virol. 2001; 75(11):5084-9. PMC: 114913. DOI: 10.1128/JVI.75.11.5084-5089.2001. View

15.

Gerlich W, ROBINSON W . Hepatitis B virus contains protein attached to the 5' terminus of its complete DNA strand. Cell. 1980; 21(3):801-9. DOI: 10.1016/0092-8674(80)90443-2. View

16.

KAPLAN P, Greenman R, Gerin J, Purcell R, ROBINSON W . DNA polymerase associated with human hepatitis B antigen. J Virol. 1973; 12(5):995-1005. PMC: 356728. DOI: 10.1128/JVI.12.5.995-1005.1973. View

17.

LE BOUVIER G, McCOLLUM R, Hierholzer Jr W, Irwin G, Krugman S, GILES J . Subtypes of Australia antigen and hepatitis-B virus. JAMA. 1972; 222(8):928-30. DOI: 10.1001/jama.222.8.928. View

18.

Lavanchy D . Viral hepatitis: global goals for vaccination. J Clin Virol. 2012; 55(4):296-302. DOI: 10.1016/j.jcv.2012.08.022. View

19.

Marion P, Oshiro L, Regnery D, Scullard G, ROBINSON W . A virus in Beechey ground squirrels that is related to hepatitis B virus of humans. Proc Natl Acad Sci U S A. 1980; 77(5):2941-5. PMC: 349522. DOI: 10.1073/pnas.77.5.2941. View

20.

Paraskevis D, Magiorkinis G, Magiorkinis E, Ho S, Belshaw R, Allain J . Dating the origin and dispersal of hepatitis B virus infection in humans and primates. Hepatology. 2012; 57(3):908-16. DOI: 10.1002/hep.26079. View